---
layout: default
title: Anamirta Cocculus Seed Conium Maculatum Flowering 
parent: 僅模型預測 (L5)
nav_order: 308
evidence_level: L5
indication_count: 0
---

# Anamirta Cocculus Seed Conium Maculatum Flowering 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ANAMIRTA COCCULUS / CONIUM MACULATUM / SILVER NITRATE / THERIDION CURASSAVICUM: Insufficient Data for Repurposing Assessment

## One-Sentence Summary

This four-component combination product — comprising *Anamirta cocculus* seed, *Conium maculatum* flowering top, silver nitrate, and *Theridion curassavicum* — has no registered market authorization and no documented approved indications in the regulatory record.
The TxGNN model returned **no predicted new indications** for this combination, and no supporting clinical trials or publications were retrieved.
At this time, a drug repurposing evaluation cannot be completed due to insufficient input data.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and even this is absent) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a mechanistic rationale cannot be constructed.

The four components suggest this may be a **homeopathic or traditional combination preparation**. *Anamirta cocculus* and *Conium maculatum* are plants historically referenced in homeopathic materia medica (typically for vestibular or neurological symptoms); silver nitrate is a conventional antiseptic/cauterizing agent; *Theridion curassavicum* is a spider venom derivative used in classical homeopathy. However, none of this contextual knowledge is sourced from the Evidence Pack and should not be treated as validated MOA data.

Because the drug has no DrugBank ID, no original indication, and no predicted indication, the relationship between original and new indication — the core of a repurposing argument — cannot be assessed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** All safety fields (key warnings, contraindications, drug–drug interactions) returned no data. The combination includes *Conium maculatum* (hemlock), which is a known toxic plant; appropriate caution is warranted pending formal toxicological review.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predicted indications for this multi-component combination, and no regulatory, safety, or mechanistic data is currently available — making a repurposing evaluation impossible at this stage.

**To proceed, the following is needed:**

- Confirm whether this product is a **homeopathic preparation** or a conventional pharmaceutical formulation, as the evaluation pathway differs substantially
- Identify any **domestic or international regulatory authorization** (if exists under a brand name not captured by the current query)
- Obtain **DrugBank ID(s)** for individual active ingredients to enable component-level TxGNN prediction
- Retrieve **MOA data** for each component via DrugBank API (Data Gap DG002)
- Retrieve **package insert warnings and contraindications** (Data Gap DG001)
- Re-run TxGNN prediction at the **individual ingredient level** rather than as a combined query string, then aggregate results
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

